At the news
? BULLISHIMPACT 8/10 8-K filed Mar 5, 2026 at 07:12 ET
Invivyd reported strong financial and clinical progress, with Q4 2025 PEMGARDA net product revenue of $17.2 million (25% YoY growth) and a year-end cash position of $226.7 million after raising over $200 million in 2H 2025. The company's pivotal DECLARATION Phase 3 trial for its COVID-19 antibody VYD2311 is fully enrolled with top-line data expected mid-2026, and the FDA granted Fast Track designation for the candidate.
- Achieved Q4 2025 PEMGARDA net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter
- 2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025
- Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026
- Fast Track designation for VYD2311 granted by FDA in December 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access